Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer
2021年7月7日 - 9:00PM
ビジネスワイヤ(英語)
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or
“Novo”) announces that Dr. Indrajit “Indra” Sinha, Ph.D. has been
appointed as Novo’s Chief Science Officer, effective June 24,
2021.
Dr. Sinha brings over 25 years of experience in various areas of
cross-disciplinary translational research, drug development,
biotechnology, technology transfer, and biopharmaceutical
compliance. His work has been extensively published in highly
reputed peer reviewed journals. Through his passion for utilizing
under-appreciated technologies and applying them in innovative ways
to achieve previously unattainable outcomes, he has created various
intellectual property and patents.
Robert Mattacchione, Novo’s Chairman and CEO, stated, “Indra
joins us at an exciting time as Novo accelerates its growth
strategy centered on providing non-catastrophic healthcare
diagnosis and subsequent treatment services and wellness products
through the integration of medical technology, advanced
therapeutics, and rehabilitative science. We welcome Indra’s
expertise and proven track record in bio-science research and the
development of personalized diagnostic products as we look to
pursue cutting edge science-based advancements in patient first
platforms.”
In 2011, Dr. Sinha founded Biomedcore Inc. Under his leadership
for science-based innovation, Biomedcore developed and patented a
unique protocol, identified as the Zgraft platform, that
effectively enables accelerated individualized prediction of cancer
progression and response to treatment. The Zgraft platform
technology has been granted a patent in multiple jurisdictions and
is being validated for clinical utility. In 2015, Biomedcore merged
with Suntrition Inc. to form Acenzia Inc. In June 2021, Acenzia was
acquired by Novo.
Dr. Sinha commented, “Novo has a clear focus and vision of how
to expand its personalized consumer engagement across all aspects
of the patient/practitioner relationship. I am excited to
contribute my knowledge to the advancement and growth of Novo’s
science related products and IP portfolio as we look forward to
building value for the Company, its shareholders and most
importantly, the patient.”
In 2001, Dr. Sinha earned a Ph.D. in infectious diseases from
University of Delhi, New Delhi, India in a collaboration with Dr.
Elisabeth Carniel's Yersinia lab at the Pasteur Institute in
France. In 1995, Dr. Sinha earned a M.Sc., Biotechnology from M.S.
University of Baroda, Vadodara, India. Dr. Sinha is currently
pursuing his MBA from Robert Kennedy College, Switzerland.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. owns Canadian and U.S.
subsidiaries which deliver, or intend to deliver, multidisciplinary
primary health care related services and products through the
integration of medical technology, advanced therapeutics, and
rehabilitative science. Our clinicians and practitioners are not
authorized to practice primary care medicine and they are not
medically licensed to prescribe pharmaceutical based product
solutions.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity offers an
essential solution to the fundamental transformation of healthcare
delivery. Specific to non-critical care, ongoing advancements in
both medical technology and inter-connectivity are allowing for a
shift of the patient/practitioner relationship to the patient’s
home and away from on-site visits to primary medical centers with
mass-services. This acceleration of “ease-of-access” in the
patient/practitioner interaction for non-critical care diagnosis
and subsequent treatment minimizes the degradation of non-critical
health conditions to critical conditions as well as allowing for
more cost-effective healthcare distribution.
Novo’s decentralized healthcare business model is centered on
three primary pillars to best support the transformation of
non-catastrophic healthcare delivery to patients and consumers. The
first pillar is building a foundation of traditional hands-on
healthcare delivery, through small and micro footprint sized clinic
facilities, within a significant service delivery network. The
second pillar is the development, integration, and deployment of
sophisticated technology, through interconnectivity, which expands
the reach of healthcare related service, beyond the traditional
clinic location, to geographic areas not readily providing advanced
healthcare service to date, including the patient’s home. The third
pillar is the development and distribution of effective wellness
product solutions allowing for the customization of patient
preventative care remedies and ultimately a healthier population.
Additionally, Novo’s science first approach to product innovation
further emphasizes Novo’s mandate to create and provide
over-the-counter preventative and maintenance care solutions.
Innovation in science as represented by the proprietary technology
assures Novo of continued cutting edge advancement in patient first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on NHL, please
visit www.novohealthnet.com.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown,
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005246/en/
Chris David, COO-President Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (206) 617-9797
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 6 2024 まで 7 2024
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 7 2023 まで 7 2024